Clinical and discovery research — Business MegaBrands 2026–27
This category covers Indian contract research organisations that run early-stage drug discovery chemistry and biology, bioavailability and bioequivalence studies, and clinical trials for pharmaceutical companies. Their work produces the data that regulators require before approving a medicine. Indian CROs shorten development timelines for generic and new drugs, and build a domestic base of clinical research skills.
Slot BMB-176 · Contract Development & Research · 3 brands in contention · Business MegaBrand: to be announced in 2027
Brands in contention
Listed alphabetically. The order does not reflect evaluation.
| Company | MegaBrands 501 |
|---|---|
| Jubilant Biosys | |
| Lambda Therapeutic Research | |
| Veeda Clinical Research |
How this category is evaluated
Every brand in this category is assessed on WCRC's 50-parameter brand evaluation model, across five pillars: Brand Positioning & Recall, Trust & Sentiment, Product, Innovation & Delivery, Sustainability, Governance & ESG, and Digital & Financial Soundness. Scores are compared within the category, and the brand with the strongest result is named the Business MegaBrand. Read the methodology
Frequently asked
Which are the leading CRO companies in India?
In the Business MegaBrands 2026–27 cohort, the brands in contention for clinical and discovery research are Jubilant Biosys, Lambda Therapeutic Research and Veeda Clinical Research. This is a list, not a ranking. WCRC will name one Business MegaBrand after its independent 50-parameter evaluation of every brand in contention.
Other categories in Contract Development & Research
All of Pharma, Life Sciences & Medtech · The 2026–27 cohort
Cite this page: WCRC, Business MegaBrands 2026–27, Clinical and discovery research (Slot BMB-176), https://www.mostvaluablebrands.com/business-megabrands/2026-27/pharma-life-sciences-and-medtech/clinical-and-discovery-research/, accessed [date].
WCRC network: WCRC International · WCRC Leaders